You had searched for:

There were no results matching the query.

You can also browse the topics below to find what you are looking for.

Support Services

  1. Download the Prescription and Service Request Form (PSRF)
  2. Fax the completed form to Shared Solutions® at 1-844-257-6127

Patients can call 1-800-887-8100, Monday–Friday, 8 am–6 pm CT.

Safety profile in clinical trials for AJOVY

Adverse reactions reported by ≥2% of patients on AJOVY and greater than placebo1,2

HALO-CM and HALO-EM (pivotal clinical trials) AJOVY 225 mg Monthly (n=290) AJOVY 675 mg Quarterly (n=667) Placebo Monthly (n=668)
Injection-site reactions* 43% 45% 38%
FOCUS phase 3b AJOVY 225 mg Monthly (n=111) AJOVY 675 mg Quarterly (n=276) Placebo Monthly (n=277)
Injection-site reactions* 9% 15% 13%

*Injection-site reactions include multiple adverse reactionsrelated terms, such as injection-site pain, induration, and erythema.

In the FOCUS phase 3b clinical trial:

  • Most injection-site reactions were rated as mild to moderate2
  • Discontinuation rate due to adverse events was <1%2
  • The most common adverse event experienced among patients receiving AJOVY included injection-site reactions (14.2%)2
  • Injection-site reactions were evaluated differently in HALO phase 3 and FOCUS studies2
  • In the phase 3 trials, injection-site reactions were assessed for erythema, induration, ecchymosis, and pain immediately and 1 hour after study drug administration. If a patient had severe injection-site induration, erythema, and/or ecchymosis and/or grade 3 (severe) or grade 4 (worst possible) injection-site pain at 1 hour after completion of study drug administration, the patient was reassessed 3 hours after study drug administration and hourly thereafter until the reaction/pain was of moderate or less severity2

 

In the HALO phase 3 clinical trials ≤2% of patients discontinued due to adverse events in the AJOVY and placebo treatment arms2

 

Most injection-site reactions were rated as mild to moderate in severity2

In both treatment arms2:

  • Less than 1% of patients experienced depression or weight gain vs <1% for placebo
  • No patients experienced memory loss vs <1% for placebo

Support Services

  1. Download the Prescription and Service Request Form (PSRF)
  2. Fax the completed form to Shared Solutions® at 1-844-257-6127

Patients can call 1-800-887-8100, Monday–Friday, 8 am–6 pm CT.

Suggestions to explore next

Continue to AJOVY Efficacy page

AJOVY helped significantly reduce monthly migraine days vs placebo1

SEE THE CLINICAL TRIAL DATA FOR AJOVY

Savings Offer coupon for AJOVY

Learn how much AJOVY may cost eligible patients

AJOVY is a monoclonal antibody that selectively targets the CGRP ligand1

see how ajovy works